Expert Review of Anti-infective Therapy最新文献_第6页

Challenges in preserving antibiotic effectiveness: time for a novel approach. 保持抗生素有效性的挑战：是时候采用新方法了。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-05-06 DOI: 10.1080/14787210.2025.2499472

Ashley Collazo, Larissa Grigoryan, Aanand D Naik, Barbara W Trautner

引用次数: 0

Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens. 品牌仿制药激增和抗微生物药物耐药性：通过世卫组织基本药物和AWaRe镜头分析巴基斯坦抗生素市场动态。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-06-02 DOI: 10.1080/14787210.2025.2511958

Saad Abdullah, Zikria Saleem, Brian Godman, Furqan Khurshid Hashmi, Abdul Haseeb, Mahmood Basil A Al-Rawi, Muhammad Usman Qamar, Mike Sharland

{"title":"Surge of branded generics and antimicrobial resistance: analyzing the antibiotic market dynamics in Pakistan through the WHO essential medicines and AWaRe lens.","authors":"Saad Abdullah, Zikria Saleem, Brian Godman, Furqan Khurshid Hashmi, Abdul Haseeb, Mahmood Basil A Al-Rawi, Muhammad Usman Qamar, Mike Sharland","doi":"10.1080/14787210.2025.2511958","DOIUrl":"10.1080/14787210.2025.2511958","url":null,"abstract":"Background: Access to safe and effective antibiotics is crucial in low- and middle-income countries (LMICs) coupled with reducing their overuse to reduce antimicrobial resistance (AMR). We sought to systematically analyze the extent of branded generic antibiotics in Pakistan, particularly Watch antibiotics, given concerns with AMR in Pakistan.Research design and methods: Data on registered antibiotics was collected from the Drug Regulatory Authority of Pakistan (DRAP) and the Pharmaguides. Two hundred and fifty-seven antibiotics were analyzed using the AWaRe classification.Results: Of these, 99 were registered in Pakistan including 91 single entities and 8 combinations, with 6,025 brands and 14,076 presentations. Distribution across AWaRe categories included Access - 37, Watch - 56, and Reserve - 6. Cephalosporins (2186 brands, 6447 presentations) and Quinolones (1333 brands, 2586 presentations) are the most prevalent, with ciprofloxacin (393 brands, 1158 presentations) leading in brand and presentation counts. Six antibiotics from the WHO Essential Medicines List lacked registered brands in Pakistan, while many available antibiotics were not included in the WHO framework.Conclusion: Extensive availability of branded generic antibiotics, particularly Watch antibiotics, in Pakistan poses a serious risk, exacerbated by the current misuse of antibiotics. Improving regulatory frameworks and strengthening stewardship are critical to reducing AMR in Pakistan along with addressing uncontrolled registration by DRAP.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"513-521"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial. 在d -甘露糖中添加胶原蛋白、蜂胶加槲皮素、凝固芽孢杆菌、透明质酸和硫酸软骨素，可避免复发性尿路感染妇女的症状和复发：一项单盲随机对照试验。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-04-03 DOI: 10.1080/14787210.2025.2487162

Gaetano Riemma, Davide Vinci, Marco La Verde, Florindo Mario Caniglia, Gaetano Scalzone, Marco Torella

{"title":"Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial.","authors":"Gaetano Riemma, Davide Vinci, Marco La Verde, Florindo Mario Caniglia, Gaetano Scalzone, Marco Torella","doi":"10.1080/14787210.2025.2487162","DOIUrl":"10.1080/14787210.2025.2487162","url":null,"abstract":"Background: To evaluate the efficacy of a new D-mannose dietary supplement containing D-mannose, Propolis-Quercetin, Bacillus Coagulans, Hyaluronic Acid and Chondroitin Sulfate with fosfomycin in reducing rUTI episodes and improving quality of life.Research design and methods: Single-blind, randomized controlled trial conducted at tertiary-care hospital in Italy. Women aged 21-65 with a history of rUTIs were randomized into three groups: fosfomycin, the dietary supplement, and a combination of both treatments. Primary outcome was frequency of rUTI episodes per month.Results: Combination therapy demonstrated greatest reduction in rUTI episodes per month at 12 months compared to fosfomycin or supplement monotherapy (0.23 ± 0.37 vs 0.58 ± 0.67 and 1.12 ± 0.96 for fosfomycin and supplement monotherapy respectively; p < 0.05) and to supplement monotherapy at 6 months (0.69 ± 1.03 vs 1.43 ± 1.33; p < 0.05), with significant improvement of ICIQ-FLUTS domains compared to other groups at 12 months (p < 0.05). Combination therapy had lower number of women matching rUTI criteria (55.32% vs 76.47% and 84%; p < 0.05) and symptoms remission at 12 months (89.36% vs 56.86% and 20%; p < 0.001).Conclusions: Combining fosfomycin and an integrated D-mannose supplement for managing rUTIs offers a potential reduction in antibiotic reliance. Further large-scale studies are recommended to confirm these findings.Trial registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT06659016).","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"523-530"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and its application in clinical microbiology. 人工智能及其在临床微生物学中的应用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-07-01 Epub Date: 2025-03-26 DOI: 10.1080/14787210.2025.2484284

Assia Mairi, Lamia Hamza, Abdelaziz Touati

{"title":"Artificial intelligence and its application in clinical microbiology.","authors":"Assia Mairi, Lamia Hamza, Abdelaziz Touati","doi":"10.1080/14787210.2025.2484284","DOIUrl":"10.1080/14787210.2025.2484284","url":null,"abstract":"Introduction: Traditional microbiological diagnostics face challenges in pathogen identification speed and antimicrobial resistance (AMR) evaluation. Artificial intelligence (AI) offers transformative solutions, necessitating a comprehensive review of its applications, advancements, and integration challenges in clinical microbiology.Areas covered: This review examines AI-driven methodologies, including machine learning (ML), deep learning (DL), and convolutional neural networks (CNNs), for enhancing pathogen detection, AMR prediction, and diagnostic imaging. Applications in virology (e.g. COVID-19 RT-PCR optimization), parasitology (e.g. malaria detection), and bacteriology (e.g. automated colony counting) are analyzed. A literature search was conducted using PubMed, Scopus, and Web of Science (2018-2024), prioritizing peer-reviewed studies on AI's diagnostic accuracy, workflow efficiency, and clinical validation.Expert opinion: AI significantly improves diagnostic precision and operational efficiency but requires robust validation to address data heterogeneity, model interpretability, and ethical concerns. Future success hinges on interdisciplinary collaboration to develop standardized, equitable AI tools tailored for global healthcare settings. Advancing explainable AI and federated learning frameworks will be critical for bridging current implementation gaps and maximizing AI's potential in combating infectious diseases.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"469-490"},"PeriodicalIF":4.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phage therapy in patients with urinary tract infections: a systematic review. 噬菌体治疗尿路感染：系统综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-04 DOI: 10.1080/14787210.2025.2513459

Romaric Larcher, Aurélien Dinh, Boris Monnin, Paul Laffont-Lozes, Paul Loubet, Jean-Philippe Lavigne, Franck Bruyere, Albert Sotto

{"title":"Phage therapy in patients with urinary tract infections: a systematic review.","authors":"Romaric Larcher, Aurélien Dinh, Boris Monnin, Paul Laffont-Lozes, Paul Loubet, Jean-Philippe Lavigne, Franck Bruyere, Albert Sotto","doi":"10.1080/14787210.2025.2513459","DOIUrl":"10.1080/14787210.2025.2513459","url":null,"abstract":"Introduction: Urinary tract infections (UTIs) caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria are challenging to treat. This systematic review evaluates bacteriophage therapy.Research design and methods: A comprehensive search was conducted in PubMed, Embase, Web of Science, and Cochrane databases. Studies reporting bacteriophage therapy in UTIs, with outcomes related to safety and efficacy, were included. Studies unrelated to UTIs or lacking clear outcomes were excluded. Bias was assessed using RoB2 and JBI appraisal tools for series and case reports. Data were synthesized narratively due to study heterogeneity.Results: From 576 articles screened, 12 studies met the inclusion criteria, comprising 89 participants, many with MDR and XDR infections. Phage therapy was generally well-tolerated. Efficacy varied, with some studies showing complete infection resolution, particularly in high-risk patients, while others reported partial or no improvement. Phage therapy often served as the sole viable treatment for XDR infections, yielding positive results despite small sample sizes and data heterogeneity.Conclusions: Phage therapy shows promise as an alternative or adjunct to antibiotics for UTIs, especially those with limited treatment options, but uncertainties remain regarding dosing and administration. Further randomized trials are needed to confirm its efficacy and safety.Protocol registration: www.crd.york.ac.uk/prospero identifier isCRD42023431617.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":4.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges. 2025年COVID-19抗病毒药物的开发：未满足的需求和未来的挑战

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-04 DOI: 10.1080/14787210.2025.2473044

Daniele Focosi, David J Sullivan, Massimo Franchini

引用次数: 0

Treatment of chronic hepatitis C infection: strategies to address poor therapy adherence. 慢性丙型肝炎感染的治疗：解决治疗依从性差的策略

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-03-30 DOI: 10.1080/14787210.2025.2486353

Robert Flisiak, Piotr Rzymski, Marta Flisiak-Jackiewicz, Michał Brzdęk, Dorota Zarębska-Michaluk

{"title":"Treatment of chronic hepatitis C infection: strategies to address poor therapy adherence.","authors":"Robert Flisiak, Piotr Rzymski, Marta Flisiak-Jackiewicz, Michał Brzdęk, Dorota Zarębska-Michaluk","doi":"10.1080/14787210.2025.2486353","DOIUrl":"10.1080/14787210.2025.2486353","url":null,"abstract":"Introduction: Non-adherence to any therapy may be related to skipping drug doses, discontinuation of therapy, or loss of follow-up. It leads to the ineffectiveness of treatment, which is associated with obvious individual health losses, significant social and financial costs, and, in the case of infectious diseases, epidemiological consequences resulting from the possibility of further spread of infection.Areas covered: This review article analyses the causes and effects of non-adherence to treatment in patients infected with the hepatitis C virus (HCV). It also presents strategies to reduce the risk of non-adherence, which can be implemented by simplifying the treatment process, improving the flow of information between the doctor and the patient, as well as improving patients' knowledge about hepatitis C infection, and facilitating the understanding of the risks associated with non-adherence.Expert opinion: Since the treatment of HCV infections is highly effective in almost all patients who complete medication, no new drugs are to be expected in the coming years. Therefore, the primary attention in the global elimination of HCV will be focused on screening programs, improving the availability of drugs, and reducing the risk of non-adherence.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"379-387"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standard dose could be better! A multicenter study of tigecycline in patients with liver failure. 标准剂量可能更好！替加环素在肝功能衰竭患者中的多中心研究。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-02-26 DOI: 10.1080/14787210.2025.2472346

Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin

{"title":"Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.","authors":"Jinlin Guo, Xinfeng Cai, Shan Wang, Hongping Wen, Jing Ren, Mi Zhou, Xingang Li, Xiaodan Yan, Shuangshuang Tian, Fang Zhang, Yanqin Liu, Wenjun Zhang, Yunyun Shao, Jianghong Cao, Xiaochun Liu, Kaixuan Hou, Dan Wei, Guan Lin","doi":"10.1080/14787210.2025.2472346","DOIUrl":"10.1080/14787210.2025.2472346","url":null,"abstract":"Background: High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose for those with severe liver impairment. This study evaluated the efficacy and safety of different tigecycline doses in this population.Research design and methods: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.Results: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.Conclusions: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"415-423"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of methicillin-resistant Staphylococcus aureus bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges ahead. 耐甲氧西林金黄色葡萄球菌血流感染的管理：对现有证据的全面回顾，重点关注当前的争议和未来的挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-10 DOI: 10.1080/14787210.2025.2487163

Alberto Enrico Maraolo, Milo Gatti, Luigi Principe, Andrea Marino, Giuseppe Pipitone, Gennaro De Pascale, Giancarlo Ceccarelli

{"title":"Management of methicillin-resistant Staphylococcus aureus bloodstream infections: a comprehensive narrative review of available evidence focusing on current controversies and the challenges ahead.","authors":"Alberto Enrico Maraolo, Milo Gatti, Luigi Principe, Andrea Marino, Giuseppe Pipitone, Gennaro De Pascale, Giancarlo Ceccarelli","doi":"10.1080/14787210.2025.2487163","DOIUrl":"10.1080/14787210.2025.2487163","url":null,"abstract":"Introduction: Bloodstream infections (BSIs) caused by Staphylococcus aureus are common worldwide, representing one of the most relevant issues in clinical infectious diseases practice. In particular, BSIs by methicillin-resistant S. aureus (MRSA-BSI) are still today a challenge since mortality burden remains elevated although decades of research.Areas covered: The following topics regarding MRSA-BSI were reviewed and discussed by resorting to best available evidence retrieved from PubMed/MEDLINE up to October 2024: i) epidemiology; ii) microbiology; iii) classification, with a focus on complicated and not complicated forms; iv) the structured approach to the patient; v) pharmacokinetics and pharmacodynamics of the main antimicrobial options; vi) controversies regarding the best therapeutic approach.Expert opinion: Despite ongoing efforts to better stratify and manage MRSA-BSI, there is no universally accepted classification system accurately distinguishing between uncomplicated/low risk and complicated/high risk forms. Biomarkers such as interleukin(IL)-10 hold promise in order to enable a more precise stratification, premise for an appropriate treatment plan. There is a theoretical rationale for implementing a combination therapy including a beta-lactam agent upfront, especially for patients considered at higher risk of unfavorable outcomes, but further data are necessary, and the same applies to newer adjuvants. Novel microbiological techniques may help in guiding antimicrobial duration.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"389-414"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Predicting the limit to ceftriaxone's use in gonorrhea treatment: impending resistance and logistical challenges. 预测头孢曲松在淋病治疗中的使用限制：即将出现的耐药性和后勤挑战。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-30 DOI: 10.1080/14787210.2025.2499471

Susannah F Vanderpool, Nardine Karam, Margaret R Hammerschlag

{"title":"Predicting the limit to ceftriaxone's use in gonorrhea treatment: impending resistance and logistical challenges.","authors":"Susannah F Vanderpool, Nardine Karam, Margaret R Hammerschlag","doi":"10.1080/14787210.2025.2499471","DOIUrl":"10.1080/14787210.2025.2499471","url":null,"abstract":"Introduction: The increasing prevalence of antimicrobial resistance in Neisseria gonorrhoeae threatens the efficacy of ceftriaxone, the last widely effective treatment for gonorrhea. Resistance mechanisms challenge the adequacy of current dosing strategies and minimum inhibitory concentration (MIC) thresholds, with treatment failures documented at MICs as low as 0.125 mcg/mL. Limited clinical and pharmacodynamic data complicate efforts to define optimal dosing and resistance breakpoints.Areas covered: This review examines the evolution of ceftriaxone dosing recommendations in response to resistance trends, explores the genetic and pharmacokinetic factors driving reduced susceptibility, and critically evaluates the CDC's MIC 'alert value' of 0.125 mcg/mL. Surveillance data are analyzed alongside pharmacokinetic/pharmacodynamic (PK/PD) models, including Monte Carlo simulations and hollow fiber infection models (HFIM). Practical challenges, including injection site tolerability, lidocaine safety, and dosing limits for intramuscular administration, are reviewed.Expert opinion: Current PK/PD data and IV tolerability studies support ceftriaxone dose escalation up to 3.5 g IM as a feasible outpatient limit for strains with MICs up to 0.5 mcg/mL. However, the MIC at which even high-dose regimens fail remains unknown. Urgent priorities include validating higher doses through clinical pharmacokinetic and outcomes studies, refining MIC thresholds by anatomical site, and evaluating novel agents for reliable pharyngeal eradication.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"343-350"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0